AstraZeneca: inconclusive trial in breast cancer

(CercleFinance.com) - AstraZeneca announces that a phase III trial evaluating Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) has been inconclusive.


The trial failed to meet its primary endpoint of improving overall survival compared with paclitaxel plus placebo, in both the overall population and a subgroup of patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN).

TNBC is difficult to treat due to the lack of known actionable biomarker targets, and chemotherapy remains the mainstay of treatment.

Despite the disappointing results, this data is important for a better understanding of this aggressive form of breast cancer, the laboratory says, which is continuing its research on Truqap and other treatments as part of its clinical development program.


Copyright (c) 2024 CercleFinance.com. All rights reserved.